Trial | FIT kit(s)/gFOBT kit | FIT positivity threshold in µg hgb/g faeces | Positive tests (%) (FIT/gFOBT) | Sensitivity (FIT/gFOBT) | Specificity (FIT/gFOBT) | No. Needed to Colonoscope/CRC (FIT/gFOBT) |
---|---|---|---|---|---|---|
FIT versus gFOBT | ||||||
Allison et al28 | HemeSelect*/Hemoccult II* | Not reported | 5.9%/2.5% | 68.8/37.1 | 94.4/97.7 | 20/15.2 |
Park et al52 | OC-Sensor†/Hemoccult II‡ | 20 | 7.9%/11.2% | 92.3/30.8 | 90.1/92.4 | 7.3/15.2 |
Parra-Blanco et al53 | OC-Light†/Hemo-Fec§ | 10 | 6.4%/1.8% | 100/57.1 | 70.4/98.3 | 9.2/7.4 |
Brenner¶ et al51 | RIDASCREEN Haemoglobin§, RIDASCREEN Haemo-Haptoglobin Complex§, OC-Sensor†/Hemoccult II‡ | 24.5 (RIDASCREEN Haemoglobin§), 7.95 (RIDASCREEN Haemo-Haptoglobin Complex§), 20 (OC-Sensor†) | 5.0% all 3 FIT**/5.0% | 60.0, 53.3, 73.3/33.3 | 95.4, 95.4, 95.5/95.2 | 12.3, 13.7, 10/22.2 |
FIT versus sFOBT | ||||||
Allison et al28 | HemeSelect*/Hemoccult Sensa* | Not reported | 5.9%/13.6% | 68.8/79.4 | 94.4/86.7 | 20/40 |
*SmithKline Diagnostics, USA.
†Eiken Chemical, Japan.
‡Beckman Coulter, USA.
§Roche Diagnostics S.L., Spain.
¶This study compared 3 FIT, RIDASCREEN Haemoglobin, RIDASCREEN Haemo-Haptoglobin Complex, OC-Sensor, with a gFOBT, Hemoccult II.
**Positivity rate for FIT was set to be equal to that of gFOBT; hence the varied positivity thresholds used (see in the preceding column).
CRC, colorectal cancer; FIT, faecal immunochemical tests; gFOBT, guaiac-based faecal occult blood tests.